VARIVAX III DIN 02246081
Status: Marketed
Holder: MERCK CANADA INC
Available to quote
Health Canada record
| Active ingredient(s) | VARICELLA VIRUS LIVE ATTENUATED (OKA/MERCK STRAIN) 1350 UNIT |
|---|---|
| Dosage form | Powder For Solution |
| Route | Subcutaneous; Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BK01 VARICELLA, LIVE ATTENUATED |
| Original market date | 02-Dec-2002 |
| Current status date | 11-Oct-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 34347 | 2024-10-11 | Supplement to a New Drug Submission (SNDS) | New route of administration |
| 7248 | 2005-07-20 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 825 | 2002-06-19 | Supplement to a New Drug Submission (SNDS) | NEW FULLY REFRIGERATOR-STABLE VACCINE |